Lipodystrophic syndrome and antiretroviral treatments in HIV-infected patients;Syndrome lipodystrophique et traitements antirétroviraux chez les patients infectés par le VIH-1

Medecine/Sciences

Volumn 17, Issue 8-9, 2001, Pages 886-892

  Savès, Marianne ^a   Mercié, Patrick ^b   Chêne, Geneviève ^a  

^a Insenn U330   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PRAVASTATIN; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN;

ADIPOCYTE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; PATHOPHYSIOLOGY; PROTEINASE INHIBITION; REVIEW;

EID: 0034804974     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/2023     Document Type: Review

References (66)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
2. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-9.
3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump " in men with HIV-1 infection. Lancet 1998; 351: 867-70.
4. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HlV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13: 465-71.
5. Garg A. Lipodystrophies. Am J Med 2000; 108:143-52.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-I protease-inhibitor-associated-lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
7. Dong K, Bausserman LL, Flynn MM, et al. Changes in body habits ami serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Iminune Def Syndr Hum Retrovirol 1999; 21: 107-13.
8. Gharakhanian S, Salhi Y, Nguyen TH, et al. Frequence of lipodystrophy and factors associated with glucose-Iipid abnormalities in a cohort of 650 patients treated by protease inhibitors. 6th Conference of Retroviruscs and Opportunistic Infections. Chicago: Fondation for Retrovirology and Human Health, 31 janvier-4 février 1999 (abstract 642).
9. Shaw A, McLean K, Eyans B. Disorders of fat distribution in HIV infection. Int J STD AIDS 1998; 9: 595-9.
10. Savès M, Rafli F, Gipeau J, et al. Factors related to the presence of fat redistribution in HIV-infectea patients treated with protease inhibitors (PI)-containing regimens, APROCO Cohort, 1999. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco: Fondation for Retrovirology and Human Health, 30 janvier-2 février 2000.
11. th Conference on Retroviruses and Opportunistic Infections. San Francisco: Fondation for Retrovirology and Human Health, 30 janvier-2 février 2000 (abstract 023).
12. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Clin Infect Dis 2000; 31: 1482-7.
13. Rozcnbaum W, Gharakhanian S, Salhi Y, et al. Clinical and laboratory characteristics of lipodystrophy in a French Cohort of HIV-infected patients treated with protease inhibitors. Antivir Ther 1999: 4 (suppl): 20.
14. Mercié P, Tchamgoué S, Dabis F, Pellegrin J-L. Lipodystrophy in HIV-1-infected patients. Lancet 1999; 3o4: 867-8.
15. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
16. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-32.
17. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang I, Pierson Jr RN. Hypertriglyceridcmia in the acquired immunodeficiency spdrome. Am J Med 1989; 86: 27-31.
18. Gnmfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoprotcins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endomnol Metab 1992; 74: 1045-52.
19. Bonnet F, Savès M, Droz C, et al. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immune Def Syndr Hum Ketrwirol 2000; 25: 199-200.
20. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HFV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-9.
21. Mercié P, Tchamgoué S, Thiébaut R, et al. Atherogcn lipid profile in HIV-1-infected patients with lipodystrophy syndrome. Eur J Intern Med 2000; 11: 257-63.
22. Sullivan AK, Nelson MR. Marked hyperlipidacmia on ritonavir therapy. AIDS 1998; 12: 1393-4.
23. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibtors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12: F167-73.
24. Periard D, Telenti A, Suclre P, et al. Atherogenic dyslipidcmia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100: 700-5.
25. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999;27:77-81.
26. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes m body composition in patients with HIV infection. J Acquir Immune Def Syndr 2000;23: 35-43.
27. Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Harm Metab Res 2000:32:367-2.
28. Tsiodras S, Mantzoros C, Hammer S, Samorc M. Effects of protease inhibitors on hyperglycemia, hypcrlipidemia, and lipodystrophy - A 5-year cohort study. Arch Intern Med 2000; 160:2050-6.
29. Vittecoq D, Zucman D, Auperin I, Passcronj. Transient insulin-dependent diabetes melfitus in an HIV-infected patient receiving didanosine. AIDS 1998; 8: 1351.
30. Chidiac C, Alfandari S, CaronJ, Mouton Y. Diabetes mellitus following treatment of AIDS with didanosine. AIDS 1995; 9: 215-6.
31. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350: 713-4.
32. Mauss S, Wolf E, Jaeger H. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors. Ann Intern Med 1999; 130: 162-3.
33. Safrin S, Gmnfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505.
34. Vigotiroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidacmia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999; 25: 225-32.
35. CapcauJ, Raffi M, Saves M, et al. Lipodystrophy and metabolic disorders in HIV-infected patients treated by protease inhibitors: is there an association? 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada: International Medical Press, 13-15 September 2000.
36. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Msceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-5.
37. Viard JP, Rakotoambinina B. Syndromes lipodystrophiques des patients infectés par le VIII recevant une multithérapie antirétrovirale: hypothèses physiopathologiques. Med Ther 2000; 6: 377-83.
38. Zvlberberg H, Nalpas B, Pol S, Bréchot C, Viard JP. Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS 2000; 14: 2055-6
39. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protcase inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Linrrt 1998; 351: 1881-3.
40. Gagnon AM, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998; 352: 1032.
41. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogencsis and increase lipolysis m vitro. Anttvir Res 2000; 47: 121-9.
42. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
43. Arnaudo E, Dalakas MC, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.
44. Chariot P, Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopatliy. Neuwmusc Disord 1991; 1: 357-63.
45. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidoyudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis and mitochondrial depletion. J Hepatol 1999; 3: 156-60.
46. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of LIPOCO study. AIDS2000; 14: 37-49.
47. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
48. Martinez E, Casamitiana R, CConget I, Gatell JM. Protease inhibitor-associated hyperinsulinaemia. AIDS 1998; 12: 2077-8.
49. Behrens G, Schmidt II, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958.
50. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958-9.
51. Henry K, Melroe H, Huebesch J, et al. Severe premature coronary artery disease protease inhibitors. Lancet 1998; 351: 1328.
52. Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV infected man with no cardiovascular risk factors who was treated with indinavir. AIDS 1998; 12: 2499.
53. Sullivan AK, Nelson MR, Moyle GJ, Newell AM, Feher MD, Gazzard BG. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS 1908; 9: 711-2.
54. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1959.
55. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131: 548.
56. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Gushing s syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 68-72.
57. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodsytrophy. Lancet 1999; 353: 1244.
58. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999; 13: 1373-5.
59. th International AIDS Conference. Durban, South Africa, 9-14juillet 2000 (abstract 1437).
60. th International AIDS Conference. Durban, South Africa, 9-14 juillet 2000 (abstract Lb114).
61. th Conference on Retroviruses and Opportunistic Infections. Chicago: Fondation for Retrovirology and Human Health, 4-8 février 2001 (abstract 668).
62. th Conference on Retroviruses and Opportunistic Infections. Chicago: Fondation for Retrovirology and Human Health, 4-8 février 2001 (abstract 673).
63. Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216-24.
64. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe dexperts. Paris: Médecine-Sciences Flammarion, 2000; 84 p.
65. Henry K, Meroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related Tipid abnormalities. Lancet 1998; 352: 1031-2.
66. th Conference on Retroviruses and Opportunistic Infections. Chicago: Fondation for Retrovirology and Human Health, 4-8 février2001 (abstract 540).